EP4516785A4 - Halogensubstituierte isoindolinverbindung und verwendung davon - Google Patents

Halogensubstituierte isoindolinverbindung und verwendung davon

Info

Publication number
EP4516785A4
EP4516785A4 EP23794677.7A EP23794677A EP4516785A4 EP 4516785 A4 EP4516785 A4 EP 4516785A4 EP 23794677 A EP23794677 A EP 23794677A EP 4516785 A4 EP4516785 A4 EP 4516785A4
Authority
EP
European Patent Office
Prior art keywords
halogen
isoindoline compound
substituted isoindoline
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23794677.7A
Other languages
English (en)
French (fr)
Other versions
EP4516785A1 (de
Inventor
Wei Hu
Liqiang Wang
Xin Cai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Fendi Pharmaceutical Co Ltd
Original Assignee
Chengdu Fendi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Fendi Pharmaceutical Co Ltd filed Critical Chengdu Fendi Pharmaceutical Co Ltd
Publication of EP4516785A1 publication Critical patent/EP4516785A1/de
Publication of EP4516785A4 publication Critical patent/EP4516785A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP23794677.7A 2022-04-29 2023-02-02 Halogensubstituierte isoindolinverbindung und verwendung davon Pending EP4516785A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210493924.4A CN114835680A (zh) 2022-04-29 2022-04-29 卤素取代异吲哚啉化合物及其应用
PCT/CN2023/074286 WO2023207241A1 (zh) 2022-04-29 2023-02-02 卤素取代异吲哚啉化合物及其应用

Publications (2)

Publication Number Publication Date
EP4516785A1 EP4516785A1 (de) 2025-03-05
EP4516785A4 true EP4516785A4 (de) 2025-08-27

Family

ID=82568710

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23794677.7A Pending EP4516785A4 (de) 2022-04-29 2023-02-02 Halogensubstituierte isoindolinverbindung und verwendung davon

Country Status (11)

Country Link
US (1) US20250282746A1 (de)
EP (1) EP4516785A4 (de)
JP (1) JP2025514398A (de)
KR (1) KR20250004840A (de)
CN (2) CN114835680A (de)
AU (1) AU2023259962A1 (de)
CA (1) CA3250950A1 (de)
CL (1) CL2024003282A1 (de)
IL (1) IL316664A (de)
MX (1) MX2024013341A (de)
WO (1) WO2023207241A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023274246A1 (zh) * 2021-06-28 2023-01-05 成都分迪药业有限公司 酰胺类化合物及其用途
CN116082301A (zh) * 2021-11-05 2023-05-09 上海美志医药科技有限公司 具有降解gspt1活性的化合物及其应用
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
US20260055077A1 (en) * 2022-08-01 2026-02-26 Suzhou Kintor Pharmaceuticals, Inc. Protein degradation agent
CN115160134B (zh) * 2022-08-10 2023-10-10 无锡科华生物科技有限公司 一种4-溴-2-甲基苯甲酸甲酯的制备方法
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
KR20240066904A (ko) * 2022-11-08 2024-05-16 주식회사 온코드바이오 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
CN115650851A (zh) * 2022-11-10 2023-01-31 无锡双启科技有限公司 一种2-氟-4-溴-6-甲基苯甲酸甲酯的制备方法
EP4660193A1 (de) * 2023-01-31 2025-12-10 Korea Research Institute of Chemical Technology Indolverbindung zur zersetzung von ikzf2 und verwendung davon
TW202438051A (zh) * 2023-02-08 2024-10-01 美商西建公司 用於選擇性降解工程化蛋白質的化合物及組合物
EP4703358A1 (de) * 2023-04-28 2026-03-04 China Pharmaceutical University Benzo-sechsgliedriges heterozyklisches gspt1-proteinabbaumittel und verwendung davon
WO2025016457A1 (zh) * 2023-07-19 2025-01-23 杭州德睿智药科技有限公司 作为GSPTs/MYC信号通量调节的新型取代杂环类化合物
WO2025092775A1 (zh) * 2023-10-31 2025-05-08 中国药科大学 一种酞嗪酮类gspt1蛋白降解剂及其应用
CN120865204A (zh) * 2024-04-30 2025-10-31 德睿智药(苏州)新药研发有限公司 作为GSPTs/CK1α双靶降解剂的新型取代杂环类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019241274A1 (en) * 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
US20230045737A1 (en) * 2018-12-05 2023-02-09 Vividion Therapeutics, Inc. Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
JP2022533260A (ja) * 2019-05-24 2022-07-21 バイオセリックス， インコーポレイテッド タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用
CN116457344A (zh) * 2020-08-03 2023-07-18 凯普托尔治疗学股份有限公司 低分子量蛋白质降解剂及其应用
US20240252101A1 (en) * 2021-06-21 2024-08-01 Skinfield Ltd. Skin characterization methods and devices
WO2023274246A1 (zh) * 2021-06-28 2023-01-05 成都分迪药业有限公司 酰胺类化合物及其用途
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
JP2025514398A (ja) 2025-05-02
EP4516785A1 (de) 2025-03-05
AU2023259962A1 (en) 2024-11-21
KR20250004840A (ko) 2025-01-08
CN116199667B (zh) 2024-05-03
WO2023207241A1 (zh) 2023-11-02
CA3250950A1 (en) 2025-03-03
CN116199667A (zh) 2023-06-02
IL316664A (en) 2024-12-01
US20250282746A1 (en) 2025-09-11
CN114835680A (zh) 2022-08-02
MX2024013341A (es) 2024-12-06
CL2024003282A1 (es) 2025-03-21

Similar Documents

Publication Publication Date Title
EP4516785A4 (de) Halogensubstituierte isoindolinverbindung und verwendung davon
EP4464709A4 (de) Sechsgliedrige cyclothiazolverbindung und verwendung davon
EP4524135A4 (de) Kinesin-kif18a-hemmer und verwendung davon
EP3919483A4 (de) Heterocyclische benzopyridonverbindung und verwendung davon
EP4368625A4 (de) Shp2-inhibitor und verwendung davon
EP4406948A4 (de) Pyridinderivat und verwendung davon
EP4141030A4 (de) Anti-cd73-antikörper und verwendung davon
EP4371991A4 (de) Benzopyrimidinverbindungen und verwendung davon
EP4159735A4 (de) Makrocyclischer jak-hemmer und verwendung davon
EP4324833A4 (de) Alkynylphenylbenzamidverbindung und verwendung davon
EP4302777A4 (de) Anti-cldn6-antikörper und verwendung davon
EP4353249A4 (de) Multiagonist und verwendung davon
EP4140998C0 (de) Substituierte pyridazinonverbindung und verwendung davon
EP4393915A4 (de) Isoindolinonverbindung und verwendung davon
EP4428153A4 (de) An gprc5d bindender antikörper und verwendung davon
EP4321535A4 (de) Anti-cntn4-antikörper und verwendung davon
EP4375299A4 (de) B7-h3-antikörper und verwendung davon
EP4506451A4 (de) Omega-transaminase-mutante und verwendung davon
EP4053161A4 (de) Anti-il-4r-einzeldomänen-antikörper und verwendung davon
EP4183781A4 (de) Schwefelhaltiges isoindolinderivat und herstellungsverfahren dafür und medizinische verwendung davon
EP4276112A4 (de) Anti-fgfr3-antikörper und verwendung davon
EP4328300A4 (de) Modifizierter tumorinfiltrierender lymphozyten und verwendung davon
EP4233916A4 (de) Komplex und verwendung davon
EP4534541A4 (de) Phosphorverbindung und verwendung davon
EP4471062A4 (de) Anti-cd73-antikörper und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

A4 Supplementary search report drawn up and despatched

Effective date: 20250728

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/04 20060101AFI20250722BHEP

Ipc: C07D 401/14 20060101ALI20250722BHEP

Ipc: C07D 405/14 20060101ALI20250722BHEP

Ipc: C07D 413/14 20060101ALI20250722BHEP

Ipc: C07D 417/14 20060101ALI20250722BHEP

Ipc: C07D 409/14 20060101ALI20250722BHEP

Ipc: A61K 31/4545 20060101ALI20250722BHEP

Ipc: A61K 31/454 20060101ALI20250722BHEP

Ipc: A61P 35/00 20060101ALI20250722BHEP

Ipc: A61P 35/02 20060101ALI20250722BHEP

17Q First examination report despatched

Effective date: 20250808